
Aura Biosciences
First pharmacological treatment for ocular melanoma
Aura BioSciences is using its proprietary VDC (virus-like particle-drug conjugates) platform to develop products to treat high unmet needs in ocular and urologic cancers.
Aura’s clinical pipeline includes AU-011, its most advanced product, which is poised to begin registrational studies in primary choroidal melanoma and which is also in Phase I studies in non-invasive muscle bladder cancer.
CEO Elisabet de los Pinos
Advent Contact Raj Parekh
Advent invested in the Series B in 2015.
Publicly Listed
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
Press Release. ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial adenomatous polyposis…
Read More
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
Press Release. Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal…
Read More
Aura Biosciences Announces Pricing of Public Offering of Common Stock
Press Release. BOSTON--(BUSINESS WIRE)-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…
Read More
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Press Release. Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating…
Read More